IS2489B - Hringtengdar amínósýrur og afleiður þeirra sem nýtast vel til lyfjagerðar - Google Patents

Hringtengdar amínósýrur og afleiður þeirra sem nýtast vel til lyfjagerðar

Info

Publication number
IS2489B
IS2489B IS5395A IS5395A IS2489B IS 2489 B IS2489 B IS 2489B IS 5395 A IS5395 A IS 5395A IS 5395 A IS5395 A IS 5395A IS 2489 B IS2489 B IS 2489B
Authority
IS
Iceland
Prior art keywords
amino acids
pharmaceutical use
cyclic amino
derivatives useful
derivatives
Prior art date
Application number
IS5395A
Other languages
English (en)
Icelandic (is)
Other versions
IS5395A (is
Inventor
Stephen Bryans Justin
Christopher Horwell David
John Thorpe Andrew
Juergen Wustrow David
Yuen Po-Wai
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS5395A publication Critical patent/IS5395A/is
Publication of IS2489B publication Critical patent/IS2489B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/51—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/53—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/417—Saturated compounds containing a keto group being part of a ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS5395A 1997-10-27 2000-03-03 Hringtengdar amínósýrur og afleiður þeirra sem nýtast vel til lyfjagerðar IS2489B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6364497P 1997-10-27 1997-10-27
US9768598P 1998-08-24 1998-08-24
PCT/US1998/019876 WO1999021824A1 (en) 1997-10-27 1998-09-23 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents

Publications (2)

Publication Number Publication Date
IS5395A IS5395A (is) 2000-03-03
IS2489B true IS2489B (is) 2009-01-15

Family

ID=26743626

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5395A IS2489B (is) 1997-10-27 2000-03-03 Hringtengdar amínósýrur og afleiður þeirra sem nýtast vel til lyfjagerðar

Country Status (30)

Country Link
US (3) US6635673B1 (enExample)
EP (1) EP1032555B1 (enExample)
JP (2) JP3756761B2 (enExample)
KR (1) KR100589066B1 (enExample)
CN (2) CN1303059C (enExample)
AR (1) AR013726A1 (enExample)
AT (1) ATE323067T1 (enExample)
AU (1) AU755800B2 (enExample)
BR (1) BR9813284B1 (enExample)
CA (1) CA2303244C (enExample)
CO (1) CO5280097A1 (enExample)
CU (1) CU23048A3 (enExample)
CY (1) CY1105062T1 (enExample)
DE (1) DE69834204T2 (enExample)
DK (1) DK1032555T3 (enExample)
ES (1) ES2260850T3 (enExample)
GE (1) GEP20094817B (enExample)
HU (1) HUP0004310A3 (enExample)
IL (1) IL134732A (enExample)
IS (1) IS2489B (enExample)
NO (1) NO327671B1 (enExample)
NZ (1) NZ503651A (enExample)
PE (1) PE122799A1 (enExample)
PL (2) PL199500B1 (enExample)
PT (1) PT1032555E (enExample)
SI (1) SI1032555T1 (enExample)
TR (1) TR200001170T2 (enExample)
UY (1) UY25223A1 (enExample)
WO (1) WO1999021824A1 (enExample)
ZA (1) ZA989740B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225502B1 (en) 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
EP1180094B1 (en) * 1999-05-26 2004-07-28 Warner-Lambert Company Fused polycyclic amino acids as pharmaceutical agents
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
HK1046401B (zh) * 1999-06-10 2005-12-02 沃尼尔‧朗伯有限责任公司 单和双取代的3-丙基-γ-氨基丁酸
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6864390B2 (en) 1999-12-08 2005-03-08 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids
DK1237847T3 (da) * 1999-12-08 2006-09-04 Warner Lambert Co Fremgangsmåde til stereoselektiv syntese af cyckliske aminosyrer
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
HUP0300833A3 (en) * 2000-06-26 2009-08-28 Warner Lambert Co Gabapentin analogues for treating sleep disorders
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
OA12504A (en) * 2001-04-19 2006-05-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids.
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE380029T1 (de) 2001-06-11 2007-12-15 Xenoport Inc Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) * 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
EP1572184A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company Gabapentin analogues for fibromyalgia and other related disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
WO2004054566A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
NZ545989A (en) 2003-09-17 2009-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
ATE516801T1 (de) 2003-10-14 2011-08-15 Xenoport Inc Kristalline form eines gamma-aminobuttersäure- analogons
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
UA82292C2 (uk) * 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
CN102429882B (zh) 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
EP1912936A2 (en) * 2005-07-18 2008-04-23 Pharmacia & Upjohn Company LLC Stereoselective synthesis of 3,4-disubstituted cyclopentanones and related compounds
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
CN101420947A (zh) * 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
JP5308350B2 (ja) 2006-12-22 2013-10-09 レコルダーティ アイルランド リミテッド α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
MX2010003394A (es) 2007-09-28 2010-04-09 Daiichi Sankyo Co Ltd Derivado de gamma-aminoacido biciclico.
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
ES2601852T3 (es) 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
ES2635354T3 (es) 2009-03-26 2017-10-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de ácido gamma-amino bicíclico
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2719677B1 (en) 2011-06-08 2017-09-06 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via claisen rearrangement
CN103582622B (zh) 2011-06-08 2015-06-10 第一三共株式会社 经由亚胺鎓盐制备双环化合物的方法
HUE040225T2 (hu) 2011-12-15 2019-02-28 Daiichi Sankyo Co Ltd Eljárás biciklikus vegyület optikai elválasztására aszimmetrikus katalizátort felhasználva
CN104245951B (zh) 2012-04-10 2018-08-24 第一三共株式会社 使用酶对二环化合物光学拆分的方法
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
CA2903000C (en) 2013-01-28 2021-10-12 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
MA39146A1 (fr) 2013-12-17 2017-11-30 Esteve Labor Dr Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
MX2016007285A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de inhibidores de la captacion de serotonina-norepinefrina (irsn) y ligandos de receptores sigma.
CN114621119A (zh) 2018-05-14 2022-06-14 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
CA3106382C (en) 2018-07-12 2023-11-07 Sichuan Haisco Pharmaceutical Co., Ltd. Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2611690A1 (de) 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
CA1085420A (en) 1977-03-24 1980-09-09 Johannes Hartenstein 1-aminomethyl-1-cycloalkane-acetic acid
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
EP0482834B1 (en) 1990-10-20 1996-01-17 Takasago International Corporation Process for producing alpha-hydroxyketones
JP3333510B2 (ja) 1991-10-02 2002-10-15 スミスクライン・ビーチャム・コーポレイション 抗アレルギー、抗炎症および腫瘍壊死因子抑制活性を有するシクロペンタンおよびシクロペンテン誘導体
US5631291A (en) 1992-05-29 1997-05-20 Bayer Aktiengesellschaft Cyclopentane- and -pentene-β-amino acids
DE4400749A1 (de) 1994-01-13 1995-07-20 Bayer Ag Neues hochenantioselektives Verfahren zur Herstellung von enantiomerenreinen Cyclopentan- und -penten-beta-Aminosäuren
HU0102040D0 (en) 1994-07-27 2001-07-30 Warner Lambert Co Purified gabapentine binding protein
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
BR9708200A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Aminoácidos cíclicos substituídos como agentes farmacéuticos
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US9858641B2 (en) * 2014-12-15 2018-01-02 International Business Machines Corporation Representing a system using viewpoints
US9419648B1 (en) * 2015-09-18 2016-08-16 Intel Corporation Supporting data compression using match scoring

Also Published As

Publication number Publication date
PL340285A1 (en) 2001-01-29
NO20002118L (no) 2000-04-26
AU9663898A (en) 1999-05-17
TR200001170T2 (tr) 2000-10-23
AU755800B2 (en) 2002-12-19
GEP20094817B (en) 2009-11-10
ATE323067T1 (de) 2006-04-15
ZA989740B (en) 1999-04-25
CU23048A3 (es) 2005-06-24
US6635673B1 (en) 2003-10-21
NO327671B1 (no) 2009-09-07
PL199500B1 (pl) 2008-09-30
NZ503651A (en) 2002-09-27
US7122678B2 (en) 2006-10-17
BR9813284A (pt) 2000-08-22
CA2303244A1 (en) 1999-05-06
HK1030768A1 (en) 2001-05-18
JP4263717B2 (ja) 2009-05-13
EP1032555A1 (en) 2000-09-06
BR9813284B1 (pt) 2012-08-21
UY25223A1 (es) 2001-08-27
IS5395A (is) 2000-03-03
EP1032555B1 (en) 2006-04-12
NO20002118D0 (no) 2000-04-26
HK1061841A1 (en) 2004-10-08
US20050159487A1 (en) 2005-07-21
IL134732A (en) 2004-03-28
CO5280097A1 (es) 2003-05-30
KR100589066B1 (ko) 2006-06-13
US20030220397A1 (en) 2003-11-27
DE69834204D1 (de) 2006-05-24
DE69834204T2 (de) 2007-03-29
CN1303059C (zh) 2007-03-07
DK1032555T3 (da) 2006-07-17
IL134732A0 (en) 2001-04-30
ES2260850T3 (es) 2006-11-01
JP3756761B2 (ja) 2006-03-15
KR20010031440A (ko) 2001-04-16
PE122799A1 (es) 1999-12-19
JP2006096758A (ja) 2006-04-13
SI1032555T1 (sl) 2006-08-31
HUP0004310A3 (en) 2001-11-28
AR013726A1 (es) 2001-01-10
HUP0004310A2 (hu) 2001-04-28
WO1999021824A1 (en) 1999-05-06
PL199794B1 (pl) 2008-10-31
US6921835B2 (en) 2005-07-26
JP2001521020A (ja) 2001-11-06
CN1500773A (zh) 2004-06-02
CN1276784A (zh) 2000-12-13
CA2303244C (en) 2005-12-06
CN1138755C (zh) 2004-02-18
PT1032555E (pt) 2006-07-31
CY1105062T1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
IS5395A (is) Hringtengdar amínósýrur og afleiður þeirra sem nýtast vel til lyfjagerðar
EE04440B1 (et) Kaparetseptori opioidpeptiidid ja farmatseutilinekompositsioon
FI973733L (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
ID24654A (id) Formulasi farmasi omeprazola
NO20002359L (no) Adenosinderivater og farmasoytisk sammensetning inneholdende derivatene
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
EE200100022A (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
HUP9902136A3 (en) Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
NO20000943L (no) 5-alkyl-2-arylaminofenyleddiksyrer og derivater
DK1073417T3 (da) Farmaceutisk aerosolformulering
DK0920302T4 (da) Farmaceutisk aerosolsammensætning
IS6181A (is) Ein- og tvíataðgengnar 3-própýl-gamma-amínósmjörsýrur
NO975513D0 (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
NO993001D0 (no) Farmas°ytiske aminofosfonsyrederivater
NO995891D0 (no) LH-RH peptidanaloger, anvendelser og farmasöytiske blandinger inneholdende disse
FI20012462L (fi) Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia
NO20006646L (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
EE04001B1 (et) Peptiidne farmatseutiline kompositsioon
DK1005342T3 (da) Farmaceutiske sammensætninger indeholdende tizoxanid og nitazoxanid
IS5186A (is) Kínólín-2-karboxýlsýru afleiða og notkun hennar sem mótlyf fyrir örvandi amínósýrur
ATE252553T1 (de) ((aminoiminomethyl)amino) alkanecarboxamide und deren therapeutische verwendungen
IL156956A0 (en) Cyclic amino acids and derivatives therefor useful as pharmaceutical agents
ZA988023B (en) Cyclic tetrapeptide derivatives and pharmaceutical use thereof
BR1100929A (pt) Derivados 1,2-difenilpirrol e uma composição farmacêutica
SI0888325T1 (en) Novel cyclic amino acids as pharmaceutical agents